Ruti Aga Banned for Six Years: How a Fake Prescription Issued by a Family Member Ended the Marathoner's Career

Ethiopian marathon runner Ruti Aga, 32, has been banned for six years by the Athletics Integrity Unit (AIU). The sanction was not imposed for an anabolic steroid but for a medication that is routine in sports medicine and entirely legal when administered by the correct route at the correct time. The ban runs to six years because the documentation the athlete produced to justify the treatment turned out to be forged — and forged by a person who held no medical registration, and who claimed to have written it on an 'old prescription pad' from a former workplace.

The AIU statement and the arithmetic of the sanction

In a statement issued on Thursday, the AIU said the two-year sanction relates to the presence of a prohibited substance, while the four-year sanction relates to tampering during the investigation. The combined six-year ban is effective from 10 September — the same date from which she had been provisionally suspended. The backdating is a procedural benefit, not a discount: time served under provisional suspension counts against the ban, so the athlete gains nothing in real terms.

The arithmetic is the clearest signal in the case. Two years is the standard outcome for a presence violation involving a Specified Substance where intent is not established. Four years is the Code's standard sanction for tampering. But the 2+4 split also indicates that the panel rejected the No Significant Fault or Negligence mitigation that would ordinarily reduce a presence sanction. Had genuine medical records and a clear route-and-timing explanation been presented, the presence charge could have been argued at the lower end — and no tampering charge would have arisen at all.

First, a technical correction: this is not a 'steroid'

Early reports on the case described methylprednisolone as a 'prohibited steroid' and stated that WADA classifies it as performance enhancing. That is technically wrong and distorts the case. Methylprednisolone is a glucocorticoid, falling under class S9 of the WADA Prohibited List — not an anabolic steroid under class S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.

The consequence is that the entire case turned on the route of administration and its timing relative to the competition, not on 'steroid use'. A therapeutic knee injection is entirely legal out-of-competition; it becomes a violation only if residues are present in an in-competition sample. In road running the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. This is precisely where a competent defence had room to work: route, dose, timing and medical necessity — clarity on these four points could have weakened the case considerably.

The forged prescription chain

The decisive fact is not the substance but the document. The athlete invoked a knee injury, but the prescription submitted was issued by a family member with no medical registration. The clinic named on the document could not be found to exist. Under questioning it was claimed that the prescription had been written on an 'old prescription pad from a former workplace' — a claim the clinic explicitly disowned.

Three independent verification points therefore failed: no clinic, no registered practitioner, and a disowned claim about the pad. This is not a clerical error. Misleading an investigation through documents is treated as a serious violation in its own right, which is why a separate four-year sanction followed. There is a near-paradox worth noting: forged documentation is itself circumstantial evidence of concealment intent, yet the panel did not escalate the presence sanction — it simply treated the two violations as independently proven.

It also matters that the tampering charge arose from an interview, not from a document alone. Statements made under questioning made the case heavier. Language and translation conditions in AIU interviews have repeatedly been a point of contention, and this case underlines that sensitivity.

A medical-governance failure, not an individual lapse

The most important insight is that this is not simply one athlete's mistake but the output of a structural gap. An athlete with a credentialed team physician has two options: obtain or apply for a Therapeutic Use Exemption, or observe the route-specific washout period so that no residue is present at competition. There is no indication either path was taken here — the opposite, in fact: a prescription was fabricated. That behaviour indicates an athlete operating without formal medical support, relying on an informal network.

This problem is widespread in East African road-running groups. Chronic knee pathology is a known risk in high-volume marathoners, and glucocorticoids are the cheapest and most available means of suppressing pain. Injured runners face pressure to protect appearance-fee income. In that environment, absent medical governance leads directly to fabricated paperwork. The forgery is not the root cause; it is downstream of it.

The athlete: a career ending at 32

Aga is 32. When the six-year ban expires she will be close to 38. The depth of Ethiopian women's marathon running is such that a 38-year-old with a doping record is, in practical terms, unselectable for the national team. The sanction is six years on paper, but in effect it is career-terminating.

Her record shows how good she was: the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. Public records indicate personal bests of approximately 2:18:34 (Berlin 2026, second) and 2:20:40 (Tokyo 2026, first) — figures not given in the original report and requiring independent verification. What is clear is that she holds no global championship medal; her standing was that of a top commercial-tier marathoner rather than a championship-race winner.

One important legal point: the ban attaches to the competition at which the sample was collected. Absent proof of earlier use, results before that date — including the 2026 Tokyo title — are not automatically annulled. The original report does not state the scope of disqualification, but under standard AIU practice, annulment of the result and prize money from the testing competition is close to certain.

Performance analysis: an absence of information

The report contains almost no performance content. The only facts are that Aga won a half marathon in China in March and that a subsequent sample returned an adverse finding. Her time, splits, field strength and the name of the race are all absent. Any performance assessment would therefore be fabrication.

The single inference available is that 'won' implies a World Athletics Label-tier elite field with in-competition testing; a routine half marathon would not attract an AIU test. It is also likely, though unstated, that the result and prize money from that race have been annulled.

Eligibility and the competitive landscape

The direct effect of the ban is that Aga is entirely outside the 2028 Olympic cycle. Ranking points accrued from the March race will almost certainly be voided, since AIU disqualification removes both results and points. The national selection pathway is effectively closed.

The effect on the competitive landscape, however, is close to nil. Ethiopian women's marathon running has world-record-class depth; the removal of a 2:18–2:20 performer does not measurably reduce national medal capacity. Compared with Kenya, Ethiopia holds the top end while Kenya holds the championship-race conversion record. Both countries are structurally so deep that one athlete's departure is invisible at national-team level — which is precisely the point.

The real subject is not competition but integrity governance. The clustering of AIU road-running cases involving tampering suggests a clear pattern: the enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier but part of a family of cases in which an initial substance violation is compounded by a fabricated or altered explanation. Because the same informal medical networks serve many athletes in the same training clusters, more similarly profiled cases are likely.

China's label-race economy and the testing economy

A further dimension is the Chinese label-race circuit. For East African marathoners it is a lucrative, low-risk income tier between Majors — large appearance fees, few races. But that same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and results from this tier will increasingly carry integrity risk.

Appeal and legal options

An appeal to the Court of Arbitration for Sport is open, typically within about 21 days of the reasoned decision. Success is unlikely, because the tampering finding is document-based and three verification points failed. There is also a dimension outside AIU jurisdiction: the criminal aspect of document forgery. The statement does not mention it, but in principle a referral to national authorities is possible. It is also unclear whether the role of an agent or management was investigated — the statement names only the family member.

The wider debate: proportionality

A six-year ban for a substance with no proven endurance benefit is itself a talking point. The decision will be read two ways. One side will treat it as evidence of AIU rigour and systemic strength. The other will call it an example of uneven enforcement against African road runners — particularly since the substance class was misdescribed in media coverage as a 'steroid', making the case appear graver to the public than it is.

Both readings have force. For the AIU, tampering is not a technicality but a foundational condition: if documents can be forged, no medical defence can ever be verified. On the other hand, it is also true that if the athlete had had formal medical support, knowledge of the TUE process and legal advice, the case might never have reached this point.

Conclusion

Three lessons emerge. First, correct classification of the substance and route is essential — a glucocorticoid and an anabolic steroid are not the same kind of offence. Second, the medical and management apparatus around an athlete matters as much as the athlete; an informal 'doctor' turned a defensible case into a career-ending ban. Third, in modern anti-doping enforcement, documentary integrity is now as central as sample integrity. The 2026 Tokyo title and three Major runner-up finishes will remain on her record — but a six-year ban at 32 is, in practical terms, the final chapter of it.